Zinnat, 125 mg 10 pcs

Zinnate is a II generation oral cephalosporin antibiotic. It acts bactericidally, disrupts synthesis of the bacterial cell wall. It has a broad spectrum of action.

It is resistant to most beta-lactamases.

Zinnate is highly active against aerobic gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis (including penicillin-resistant strains and except for rare methicillin-resistant strains), Streptococcus pyogenes, Streptococcus pneumoniae, Streptococcus group B (Streptococcus agalactiae), Streptococcus mitis (viridans group), Bordetella pertusis; aerobic gram-negative bacteria: Escherichia coli, Klebsiella spp., Proteus mirabilis, Providencia spp, Proteus rettgeri, Haemophilus influenzae (including ampicillin-resistant strains), Haemophilus parainfluenzae (including ampicillin-resistant strains), Moraxella (Branhamella) catarrhalis, Neisseria gonorrhoeae (including penicillinase-producing and non-producing strains), Neisseria meningitidis, Salmonella spp.Anaerobic gram-positive bacteria: Peptococcus spp, Peptostreptococcus spp, Clostridium spp, Propionibacterium spp; anaerobic gram-negative bacteria: Bacteroides spp, Fusobacterium spp; also active against Borrelia burgdorferi.

Cefuroxime is resistant to Clostridium difficile, Pseudomonas spp., Campylobacter spp., Acinetobacter calcoaceticus, Listeria monocytogenes, methicillin-resistant strains of Staphylococcus aureus, methicillin-resistant strains of Staphylococcus epidermidis, Legionella spp.

In in vitro studies it has been shown that when combining cefuroxime with antibiotics from the group of aminoglycosides an additive effect is observed and in some cases synergism.

Indications

Treatment of infectious and inflammatory diseases caused by microorganisms sensitive to the drug:

Active ingredient

Composition

1 tablet contains cefuroxime 250 mg;

auxiliary substances:

MCC,

croscarmellose sodium,

sodium lauryl sulfate,

How to take, the dosage

A single dose for adults and children over 12 years is usually 250 mg 2 times a day.

In severe lower respiratory tract infections, 500 mg 2 times a day.

Infections of the urinary tract are prescribed in 125 mg 2 times a day, in pyelonephritis 250 mg 2 times a day.

In the treatment of uncomplicated gonorrhea 1 g is prescribed once.

In Lyme disease 500 mg 2 times a day for 20 days.

Interaction

Special Instructions

In prolonged use of Zinnate increased growth of resistant microorganisms (Candida, Enterococci, Clostridium difficile) is possible that may require discontinuation of treatment.

In case of diarrhea during treatment with antibiotics, including Zinnate, the possibility of pseudomembranous colitis should be kept in mind.

The treatment with Zinnate for Lyme disease sometimes causes a Jarisch-Hersheimer reaction.

This reaction is a direct consequence of the bactericidal effect of Zinnate on the causative agent – Borrelia burgdorferi spirochaete.

Patients should be explained that this is a frequent and common, spontaneous consequence of antibiotic treatment for Lyme disease.

Contraindications

Hypersensitivity to antibiotics of the cephalosporin group.

Cautious use in the first trimester of pregnancy and lactation.

Side effects

Gastrointestinal system disorders: nausea, vomiting, diarrhea; temporary increase in the activity of liver enzymes (ALT, AST, LDH), jaundice; there have been cases of pseudomembranous colitis.

Hematopoietic system: hemolytic anemia, eosinophilia, neutropenia, thrombocytopenia, leukopenia (sometimes severely expressed).
Allergic reactions: skin rash, pruritus, urticaria, fever, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, serum sickness; in single cases – anaphylaxis.

CNS disorders: headache.

Others: positive Coombs reaction.

Similarities